Cardiovascular effect of a new 1,5-benzothiazepine derivative TA-993 in anesthetized dogs.
TA-993 is a new 1,5-benzothiazepine derivative having l-cis configuration and shows a potent antiplatelet aggregating action. We studied its cardiovascular effect in anesthetized dogs by using diltiazem as a reference compound. TA-993 (> or = 10 microg/kg, i.v.) significantly increased blood flows of common carotid, brachial, and femoral arteries. The peak of its effect was observed approximately 60 min after the administration, and the peak level was maintained until > or = 300 min after the administration. TA-993 (100 microg/kg, i.v.) slightly increased cardiac output in the same manner. However, TA-993 did not cause any persistent effects on arterial pressure, LVdP/dtmax, or vertebral, coronary, superior mesenteric, and renal blood flows. TA-993 caused concentration-dependent vasorelaxation in the isolated canine femoral artery contracted with 40 mM K+, but its potency was approximately 1/20 that of diltiazem. The increasing action of TA-993 on femoral blood flow was completely inhibited by pretreatment with hexamethonium in anesthetized dogs. These results indicate that TA-993 has a selective increasing action on common carotid, brachial, and femoral blood flows and suggest that the action is mediated by the autonomic nervous system.
Kaburaki
M
M
Pharmaceutical Development Research Laboratory, Tanabe Seiyaku Co., Ltd., Toda, Saitama, Japan.
Narita
H
H
Yabana
H
H
Karasawa
T
T
Doi
H
H
Murata
S
S
D000818:Animals; D001916:Brachial Artery / Q000187:drug effects; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002339:Carotid Arteries / Q000187:drug effects; D004110:Diltiazem / Q000031:analogs & derivatives* / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004562:Electrocardiography; D005260:Female; D005263:Femoral Artery / Q000187:drug effects; D005730:Ganglionic Blockers / Q000494:pharmacology; D006439:Hemodynamics / Q000187:drug effects*; D018738:Hexamethonium / Q000494:pharmacology; D007275:Injections, Intravenous; D008297:Male; D012039:Regional Blood Flow / Q000187:drug effects; D013997:Time Factors; D014664:Vasodilation / Q000187:drug effects
D002317:Cardiovascular Agents; D005730:Ganglionic Blockers; C097363:TA 993; D018738:Hexamethonium; D004110:Diltiazem